| 2.89 Real-Time Quote |  -0.12 / -3.99%Today’s Change | 2.25 Today|||52-Week Range 14.08 | -64.10% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $156.2M |
Company Description
AVEO Pharmaceuticals, Inc. does business as AVEO Oncology is a cancer therapeutics company, which is discovering, developing and commercializing targeted therapies to impact patients lives. The company's product candidate, Tivozanib, which is designed to provide an optimal blockade of the vascular endothelial growth factor, or VEGF, pathway by inhibiting all three VEGF receptors. It also has a pipeline of monoclonal antibodies, including ficlatuzumab, a product candidate that is currently in phase 2 clinical developments, derived from its Human Response Platform, a novel method of building preclinical models of human cancer. The company was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
Employees
Shareholders
| Other institutional | 35.04% |
| Mutual fund holders | 34.72% |
| Individual stakeholders | 13.59% |
Top Executives
| Tuan Ha-Ngoc, MBA | President, Chief Executive Officer & Director |
| Elan Z. Ezickson | Chief Operating Officer & Executive Vice President |
| David B. Johnston, MBA | Chief Financial Officer |
| Anna Berkenblit, MD | Vice President & Head-Clinical Research |
| Albert Dauray | Vice President-Information Technology |
.
